Product Name: Human DR5 / TRAILR2 Antibody (Drozitumab, Research Use)
Catalog Number: NBR-0463
Target Name: DR5 / TRAILR2
Trade Name: Drozitumab
Antibody Drug Description: Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: DR5 / TRAILR2
Synonyms: CD262; DR5; KILLER; TRAIL-R2; TRAILR2; TRICK2A; TRICKB; TNFRSF10B
Target Description: Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.
Ensembl: ENSG00000120889
Uniprot: O14763